January 23, 2024
Weil is advising Sanofi in connection with its acquisition of Inhibrx, Inc., a publicly traded clinical-stage biopharmaceutical company, whereby, following the spin-off of Inhibrx’s non-INBRX-101 assets into a new publicly traded company, Sanofi will acquire Inhibrx in a transaction valued at up to $2.2 billion. The transaction is expected to close in Q2 2024, subject to the completion of New Inhibrx spin-off transaction and other customary closing conditions, including receipt of regulatory approvals and approval by Inhibrx’s shareholders.
Sanofi is an innovative global healthcare company spread across some 100 countries that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms.
The Weil team advising Sanofi is led by Mergers & Acquisitions partner Michael J. Aiello and includes Merger & Acquisitions partner Amanda Fenster, counsel Katie Thomas and associates Julia Sichun Liu, Jack Parsons, Alex Schnapp and Jess Serviss (Not Yet Admitted in New York); Banking & Finance partner Heather Viets and associate Olivia Franzblau; Capital Markets partner Alexander Lynch and associate Federica Marini; Antitrust partner John Scribner, counsel Michael Naughton and associate Emma D’Arpino; Employment partner Rebecca Sivitz and associate Brett Bonfanti; Executive Compensation & Benefits partners Regina Readling and Paul Wessel and associates Ace Szmolyan and Connor Wax (Not Yet Admitted in New York); Regulatory Transactions partners Shawn Cooley, John O’Loughlin and Timothy Welch, counsel Nathan Cunningham and associates Christina Carone and Jessica Nash; Tax partners Graham Magill and Joseph Pari and associate Alex Dobyan; and Technology & IP Transactions partners Olivia Greer and Jeffrey Osterman, counsel Kane Wishart and associates Alexis Bello, Sabrina Chishti, Dominic Farchione, Adeline Park and Mirish Shah.